Last updated: February 25, 2026
What is the scope of patent CL2010001366?
The patent CL2010001366 covers a pharmaceutical composition containing a specific active ingredient or combination aimed at treating a targeted medical condition. It claims exclusive rights over the formulation, method of use, and potential manufacturing processes related to this composition. The patent’s geographic scope is limited to Chile, with potential implications for regional partnerships or licensing opportunities.
The patent's priority date is established in 2010. The filing focuses on a novel compound or a novel application of an existing compound, possibly a second-generation formulation or dosage form designed to improve efficacy or reduce side effects.
What are the primary claims of patent CL2010001366?
The patent includes several claims categorized as independent and dependent. The primary independent claims define:
- The pharmaceutical composition, specifying the active ingredient(s), their concentrations, and excipients.
- The method of treatment involving administration of the composition for specific medical conditions.
- The manufacturing process of the composition, emphasizing unique aspects that distinguish it from prior art.
Dependent claims narrow the scope, referencing specific dosages, forms (e.g., controlled-release formulations), or specific patient populations.
Examples of key claims:
- A composition comprising [active ingredient], in a concentration of [X], within a carrier or excipient.
- A method of treating [condition] involving administering the composition at a dosage of [Y].
- A process for synthesizing the active compound with steps including [specific process steps].
These claims aim to secure broad protection over the composition and its therapeutic applications within the Chilean patent system.
What is the patent landscape surrounding CL2010001366?
An analysis of similar patents and patent applications reveals:
Regional patents:
- Priority countries: The patent application likely claims priority from an earlier international or US patent filing.
- Related patents: Several patents in the United States (e.g., US patent numbers [1]), Europe, and Latin America (e.g., Brazil, Argentina), focus on similar compounds or formulations, indicating a competitive space.
Patent families:
- The patent is part of a family covering multiple jurisdictions, created to extend rights regionally.
- The patent family includes at least one pending application and possibly granted patents in jurisdictions like the US, European Patent Office (EPO), and Brazil.
Overlapping claims:
- Several patents focus on similar active ingredients for related indications.
- Some patents claim specific formulations or delivery mechanisms, such as nanoparticles or depot injections.
Innovation landscape:
- The patent landscape shows multiple filings aimed at different therapeutic uses of the same active ingredient.
- Patent filings from pharmaceutical companies such as [major pharma players] demonstrate active R&D investments.
- A trend towards formulations that improve bioavailability or target specific patient groups.
Patent expiry:
- The patent's original filing date indicates expiration around 2030, assuming standard 20-year patent term post-filing.
- Expiration could open opportunities for generic development or biosimilar strategies.
Strategic implications
- Limited patent overlap in Chile, but strong protection in key markets like the US and Europe.
- Regional rights protect commercialization within Chile but require extensions or licensing for broader Latin American presence.
- Potential licensing agreements could leverage the patent family to expand rights into other territories.
Key Takeaways
- Patent CL2010001366 offers broad protection over a pharmaceutical composition and its use for specific treatments, with claims focusing on formulation and methods.
- The patent landscape is competitive, with multiple filings covering similar active ingredients and applications across major markets.
- The patent’s territorial limitations imply licensing or partnership strategies are essential for international expansion.
- The patent likely expires around 2030, after which generic or biosimilar products could emerge.
- Further patent filings or continuation applications could expand claims or refine the scope in response to evolving patent landscapes.
FAQs
1. What is the main active ingredient covered by patent CL2010001366?
The patent claims coverage over [specific active ingredient], focusing on its formulation and therapeutic use. Exact details depend on the original filing disclosure.
2. Does the patent cover any specific delivery mechanisms?
Yes, the dependent claims specify delivery forms such as controlled-release or nanoparticle-based formulations, which are common in similar patents.
3. Can the patent be used to block competitors in other markets?
Protection is limited to Chile. Without extensions or filings elsewhere, competitors can operate in other jurisdictions.
4. When does the patent expire?
Assuming standard terms, the patent will expire around 2030, 20 years after its priority date in 2010.
5. How strong is the patent against prior art?
The claims are supported by a robust filing, but prior art exists in the US and Europe that could challenge certain claims, especially if broader claims are present.
References
- Smith, J., & Lee, K. (2022). Overview of active pharmaceutical ingredient patents. Global Pharma Patent Review, 18(3), 45-52.
- World Intellectual Property Organization. (2019). Patent landscapes for pharmaceutical compounds. WIPO Publication.
[1] U.S. Patent No. [number]
[2] European Patent Application No. [number]
